Endocrine Neoplasm

The AKAP9-BRAF fusion gene was found in 3/28 tumor samples of radiation-associated papillary thyroid carcinoma, and no samples of non-radiation associated papillary thyroid carcinoma. This fusion was … (full text at CIViC)

PMID 15630448 · Ciampi et al., 2005 · Open in CIViC

The results proposes a potential that BIRC7 represses PTC cell autophagy, causing increase in the migration and mtastatic ability of these cells

PMID 32064154 · Liu et al., 2020 · Open in CIViC

Thyroid nodule with BRAF V600E mutation is highly correlated with papillary thyroid cancer.

PMID 24570209 · Crescenzi et al., 2014 · Open in CIViC

Unlike other studies that suggest a poorer outcome, BRAF mutation in this study was not correlated with poorer prognosis in papillary thyroid cancer.

PMID 24354346 · Walczyk et al., 2014 · Open in CIViC

Immunohistochemical analyses of PD-L1 protein was retrospectively performed on 251 archived FFPE surgical tissues (66 benign thyroid nodules and 185 papillary thyroid carcinomas PTC, E1L3N antibody). … (full text at CIViC)

PMID 27086918 · Chowdhury et al., 2016 · Open in CIViC

Patients with Merkel Cell Carcinoma (n=26) were enrolled to receive pembrolizumab. Of these patients, 25 were evaluated for response rate to pembrolizumab and PD-L1 (CD274) expression. The response ra… (full text at CIViC)

PMID 27093365 · Nghiem et al., 2016 · Open in CIViC

A 35 year-old patient presented with a grade 3 pancreatic neuroendocrine tumor and liver metastasis. Whole genome sequencing and RNAseq revealed a previously undescribed somatic translocation between … (full text at CIViC)

PMID 31160355 · Williamson et al., 2019 · Open in CIViC

A preclinical study to evaluate the efficacy of targeting the overexpressed CHEK1 cell cycle chekpoint kinase, including both miRNA and Prexasertib-induced inhibition. Both in vitro and in vivo, Prexa… (full text at CIViC)

PMID 28490518 · Sen et al., 2017 · Open in CIViC

In a phase II trial, patients with DLL3-expressing small cell lung carcinoma were treated with rovalpituzumab tesirine. Only patients with 1% or more tumor cells expressing DLL3 were enrolled. In this… (full text at CIViC)

PMID 31506387 · Morgensztern et al., 2019 · Open in CIViC

74 patients with small-cell lung cancer and eight with large-cell neuroendocrine carcinoma received at least one dose of rovalpituzumab tesirine in a phase 1 trial. 11 (18%) of 60 assessable patients … (full text at CIViC)

PMID 27932068 · Rudin et al., 2017 · Open in CIViC

In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells d… (full text at CIViC)

PMID 24893891 · Cross et al., 2014 · Open in CIViC

From a retrospective review of 38,095 tumor samples from 33,997 patients using DNA sequencing (MSK-IMPACT) and RNA sequencing (MSK-Fusion panel) identified 87 tumors with NTRK1-3 fusions. One case of … (full text at CIViC)

PMID 31375766 · Solomon et al., 2020 · Open in CIViC

Of 351 primary thyroid carcinoma patients assessed by targeted gene rearrangement next-generation assay, 11 cases (3.1%) had NTRK rearrangement. Only one case of EML4::NTRK3 fusion (e2,e13) with an in… (full text at CIViC)

PMID 32457407 · Chu et al., 2020 · Open in CIViC

This report details 2 case studies in relapsed HER2 positive SCLC. In the first case, a 50 pack-year patient showed intense non-mutant HER2 expression by IHC without DNA amplification, and had underg… (full text at CIViC)

PMID 25601188 · Kinehara et al., 2015 · Open in CIViC

A 53 year old female patient had PTC treated with surgery and multiple brain metastases. TERT c.-124C.T mutation and ETV6::NTRK2 fusion was found in pleural biopsy and cerebellar resection specimens.… (full text at CIViC)

PMID 35171659 · Park et al., 2022 · Open in CIViC

Prasad et al queried the histopathology of 28 Papillary Thyroid Carcinomas (PTCs) from patients ages 6-18 years (20 females, 8 males). None had significant exposure to radiation. 5 / 27 PTCs (18.5%) h… (full text at CIViC)

PMID 26784937 · Prasad et al., 2016 · Open in CIViC

A 79 year old patient with prior 5-year history of Graves' disease presented with follicular thyroid carcinoma. Two mutations NRAS p.Q61K and GNAS p.R201H were detected. The thyroid cancer manifested … (full text at CIViC)

PMID 26788326 · Lu et al., 2016 · Open in CIViC

Follicular thyroid cancers harboring RAS mutations have limited aggressiveness in the absence of TERT mutations. 2/2 follicular thyroid cancer patients with co-mutations in NRAS (10 Q61R and 1 Q61K) o… (full text at CIViC)

PMID 25448848 · Muzza et al., 2015 · Open in CIViC

Phase 2 study of pazopanib in pretreated advanced neuroendocrine tumors. Study found that patients with immunoexpression of VEGFR2 (KDR) above the median had longer PFS (12.6 months vs 9.1 months, P=… (full text at CIViC)

PMID 26063633 · Grande et al., 2015 · Open in CIViC

Study evaluated 42 cases with aggressive fibromatosis were genotyped for the M541L (c.1621 A>C; rs3822214) was evaluated and compared to gender- and age-matched 126 healthy controls. In 4/7 cases with… (full text at CIViC)

PMID 21757432 · Grabellus et al., 2011 · Open in CIViC

Two patients diagnosed with oncocytic thyroid carcinoma (hurthle cell thyroid carcinoma) were evaluated for MEN1 mutations. One tumor showed 592-end deletion of MEN1 and the other showed a 521 frames… (full text at CIViC)

PMID 25625803 · Kasaian et al., 2015 · Open in CIViC

Neuroendocrine tumors (NETs) of the pancreas (PNETs) and bronchus (BNETs) have mutations of the multiple endocrine neoplasia type 1 (MEN1) gene, which encodes menin that modifies histones by interacti… (full text at CIViC)

PMID 28504695 · Lines et al., 2017 · Open in CIViC

Patient small-cell lung cancer cells with c-MET juxtamembrane mutations (R988C or T1010I) were shown to have increased tyrosine phosphorylated cellular proteins such as paxillin, a focal adhesion cyto… (full text at CIViC)

PMID 14559814 · Ma et al., 2003 · Open in CIViC

Among those patients who received temozolomide-based therapy in this study, the median progression-free survival for patients whose tumors showed intact MGMT expression was 9.3 months compared with 19… (full text at CIViC)

PMID 19118063 · Kulke et al., 2009 · Open in CIViC

A preclinical study to evaluate the efficacy of targeting the overexpressed CHEK1 cell cycle chekpoint kinase, including both miRNA and Prexasertib-induced inhibition. Both in vitro and in vivo, Prexa… (full text at CIViC)

PMID 28490518 · Sen et al., 2017 · Open in CIViC

In patients with follicular thyroid carcinoma, those with mutations in NRAS at codon 61 did not have significantly different overall survival than patients with wild-type NRAS (p=0.36).

PMID 22650231 · Fukahori et al., 2012 · Open in CIViC

Follicular thyroid cancers harboring RAS mutations have limited aggressiveness in the absence of TERT mutations. 2/2 follicular thyroid cancer patients with co-mutations in NRAS (10 Q61R and 1 Q61K) o… (full text at CIViC)

PMID 25448848 · Muzza et al., 2015 · Open in CIViC

PAX8–PPARG gene fusions were found in 12/33 follicular thyroid carcinoma tumor samples, but were rarely found in thyroid Hürthle cell tumors.

PMID 12727991 · Nikiforova et al., 2003 · Open in CIViC

A case report of an 86-year old patient with metastasized Merkel cell carcinoma who achieved a complete clinical response under therapy with the PI3K-inhibitor Idelalisib.

PMID 26466009 · Shiver et al., 2015 · Open in CIViC

A 51-year-old woman with an invasive small-cell cancer of the ureter showed a durable complete response at 3-years when treated with AZD7762 (an ATP-competitive checkpoint kinase inhibitor) and irinot… (full text at CIViC)

PMID 24934408 · Al-Ahmadie et al., 2014 · Open in CIViC

Study evaluated a total of 50 small cell lung cancer patients with extensive stage disease. Multivariate analysis identified RB1 as a factor in predicting response to first-line chemotherapy (odds rat… (full text at CIViC)

PMID 26802149 · Dowlati et al., 2016 · Open in CIViC